Safety and efficacy of convalescent plasma for COVID-19 in the pre-vaccine era, and implementation in a large healthcare system: A phase I/II randomized, multicentre clinical trial (PC-COVID)

Identificadores
URI: http://hdl.handle.net/10498/40626
DOI: 10.1016/J.EIMC.2026.503166
ISSN: 1578-1852
ISSN: 0213-005X
Statistics
Metrics and citations
Metadata
Show full item recordAuthor/s
Caponcello, Maria Giulia; Macías Sánchez, Maria del Mar; Macías, Juan; Aguilar Guisado, Manuela; Romero Palacios, Alberto
; Retamar Gentil, Pilar; Márquez-Gómez, Ignacio; Martínez-Marcos, Francisco Javier; López Cardenas, Salvador
; Marrugal Lorenzo, Jose Antonio; Quijano Ruiz, Blanca; Mata, Rosario; Carmona Sánchez, Gloria; Oyonarte, Salvador; Rodríguez Baño, Jesús
Date
2026-03-31Department
Cirugía; MedicinaSource
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 44, Núm. 6, 2026Abstract
Introduction: A phase 2 trial was conducted to evaluate the safety and efficacy of convalescent plasma (CP) for patients admitted with COVID-19 in the pre-vaccine era. Methods: CP was compared to standard of care (SoC) in a randomized clinical trial in patients admitted with COVID-19 pneumonia and with either hypoxia and/or some underlying condition from April to December 2020 in 15 hospitals in Andalusia, Spain. The primary endpoints were adverse events and failure (all-cause death and need for mechanical ventilation during the first 21 days). Result: The procedure for CP was developed and worked properly. Overall, 72 patients of 88 evaluated were recruited (37 and 35) assigned to CP and SoC. Median duration of COVID-19 related symptoms was 7 and 6 days, and median oxygen saturation at randomization was 93% and 92.5% in experimental and control arms, respectively. Overall, 8 (21.6%) patients in the experimental CP group (non related to CP) and 8 (22.9%) in the control group developed grade 3 adverse events (relative risk [RR] 0.94; 95% CI: 0.39–2.24); failure occurred in 3 (8.1%) and 4 (11.4%) patients, respectively ([RR] 0.94, CI: 0.14–6.35 for both events). No differences in secondary endpoints (change in inflammatory parameters, negativization of SARS-CoV-2 PCR or duration of hospital stay) were found. Conclusions: The results suggested that CP is safe for use in COVID-19 patients, although no significant efficacy signal could be observed. A successful regional system for CP administration was developed.
Subjects
COVID-19; Convalescent plasma; Clinical trialCollections
- Artículos Científicos [12034]





